<i>NTRK1</i> rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

201558 citationsJournal Articlediamond Open Access

Authors

Su Jin Lee · Sungkyunkwan University

Gang Gary Li · Ignyta (United States)

Seung Tae Kim · Samsung Medical Center

Min Eui Hong · Samsung Medical Center

Jiryeon Jang · Samsung Medical Center

Nara Yoon · Samsung Medical Center

Soo Min Ahn ·

Abstract

TrkA IHC is an effective, initial screening method for NTRK1 rearrangement detection in the clinic. Inhibition of the TrkA kinase is a promising targeted therapy for cancer patients whose tumors harbor a NTRK1 rearrangement.

Topics & Keywords

HER2/EGFR in Cancer Research Chronic Lymphocytic Leukemia Research Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Oncotarget

Volume 6, Issue 36, pp. 39028-39035

DOI: 10.18632/oncotarget.5494

Field-Weighted Citation Impact: 3.66